Analysts weighed in on biotech companies Opko Health Inc.(NYSE:OPK) and Inovio Pharmaceuticals Inc (NASDAQ:INO) in light of new reports and pipeline updates from the …
Although early stage biopharma companies do not make a profit, their pipeline study updates can send shares soaring… or crashing. Analysts weigh in …
Opko Health Inc. (NYSE:OPK) announced dosing of the first patient in a Phase 2a study evaluating the safety of a long-acting Factor VIIa …
Opko Health Inc. (NYSE:OPK) announced through its subsidiary GeneDx, results from a retrospective review of molecular diagnostic testing by Whole Exome Sequencing (WES).
Opko Health Inc. (NYSE:OPK) announced that VARUBI™ (rolapitant), an NK-1 receptor antagonist, is now available in the United States.
Jefferies analyst Brandon Couillard came out with a research report on Opko Health Inc. (NYSE:OPK) Friday, assuming coverage with a Hold rating and raising the price target to …
Opko Health Inc. (NYSE:OPK) announced a global license agreement with The Scripps Research Institute (TSRI) for the development and commercialization of novel lipoprotein …
Opko Health Inc. (NYSE:OPK) announced that the U.
On August 7, Opko Health Inc. (NYSE:OPK) CEO Phillip Frost purchased more than one million shares of OPK in five separate transactions valued …
Opko Health Inc. (NYSE:OPK) announced that additional data from OPKO’s hGH-CTP pediatric Phase 2 clinical trials summarized in two abstracts entitled, “12 month …
